A
AI Proteins
A newly founded biotechnology company focused on the design and engineering of synthetic miniprotein therapeutics
About AI Proteins
AI Proteins is a biotech startup that aims to revolutionize protein-based therapeutics. Founded in late 2021, the company has developed a unique platform that combines synthetic biology, robotics, automation, and artificial intelligence to design, build, and develop miniprotein medicines. These are smaller, more cost-effective versions of traditional protein-based drugs, with the potential for a variety of administration methods.
Read full description
The company's platform allows for complete structural control over the miniproteins, enabling the creation of patentable drugs with the best characteristics of small molecules and biologics. This means they can create drugs that are highly specific, durable, and inexpensive, with nearly unlimited therapeutic potential.
AI Proteins primarily serves the healthcare industry, focusing on inflammation, oncology, and metabolic diseases. They have identified novel drug candidates against a multitude of high-value therapeutic targets and are currently developing their own pipeline of drugs. Additionally, they are exploring partnerships to maximize the value of their innovations.
The business model of AI Proteins is based on the development and commercialization of their proprietary miniprotein medicines. They generate revenue through the sale of these drugs and potentially through partnerships with other companies in the healthcare industry.
The team at AI Proteins is comprised of experienced protein engineers and drug developers, including former heads of protein design at renowned institutions and lecturers at Harvard Medical School. Their combined expertise in computational protein design, structural biology, biochemistry, and synthetic miniprotein engineering positions the company well for success in the biotech market.
At a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- Boston, United States
- Employees
- 39
- Open positions
- None listed
- Dealroom signal
- 83.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Core AI, Synthetic Biology, Spinout, Tech for Biotech and Pharma, AI Drug Discovery
- Technology
- Artificial Intelligence, Deep Tech
- Business model
- SaaS
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Nov 2025 | $42M | $166M | Sante Ventures · Mission BioCapital | ↗ |
| DEBTDebt | Apr 2024 | $5M | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for AI Proteins is 1.6K monthly website visits, down 79.2% over the last three months. AI Proteins's team grew 5.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
- LCLightchain Capital
- CVCobro Ventures
Series A2 investors entered at this stage
Sante Ventures
Mission BioCapital
Other known investors3 additional known investors
Children’s Hospital Boston
Harvard Medical School
Institute for Protein Innovation
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about AI Proteins on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See AI Proteins’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.